Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Forest Laboratories



) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.5%. By the end of trading, Forest Laboratories rose $0.50 (1.1%) to $44.25 on average volume. Throughout the day, 2,417,789 shares of Forest Laboratories exchanged hands as compared to its average daily volume of 1,620,100 shares. The stock ranged in a price between $42.68-$44.87 after having opened the day at $44.00 as compared to the previous trading day's close of $43.75. Other companies within the Drugs industry that increased today were:

IntelliPharmaCeutics International



), up 56.0%,

Biocryst Pharmaceuticals



), up 21.5%,

Bacterin International Holdings



), up 16.9% and

DARA Biosciences



), up 13.0%.

Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products primarily in the United States and Europe. Forest Laboratories has a market cap of $11.7 billion and is part of the health care sector. Shares are up 23.9% year to date as of the close of trading on Monday. Currently there are 7 analysts that rate Forest Laboratories a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates

Forest Laboratories

as a


. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front,

Mast Therapeutics



), down 33.4%,

Ampio Pharmaceuticals



), down 13.5%,

Aoxing Pharmaceutical Company



), down 12.0% and

Durata Therapeutics



), down 8.2% , were all laggards within the drugs industry with




) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.